Georgia's Online Cancer Information Center

Leukemia Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Leukemia
Cancer Type = Leukemia
There are currently 88 active Leukemia clinical trials in Georgia.
1.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Cancer Type
Leukemia
NCT ID
NCT05006716
Protocol IDs
BGB-16673-101
NCI-2022-01959
2022-502157-33-00
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
4.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03802695
Protocol IDs
OGFT001-001
NCI-2019-01953
Treatment Sites (1)
5.
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Cancer Type
Leukemia
NCT ID
NCT05918692
Protocol IDs
COVALENT-103
NCI-2023-06835
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT03420183
Protocol IDs
CIRM-0001
NCI-2018-00270
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05482971
Protocol IDs
EXCEED ET / A22-301
NCI-2023-00605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia
NCT ID
NCT05131022
Protocol IDs
NX-5948-301
NCI-2023-01623
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia
Cancer Type
Leukemia
NCT ID
NCT05761171
Protocol IDs
AALL2121
AALL2121
NCI-2023-00503
11.
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCT ID
NCT04065399
Protocol IDs
SNDX-5613-0700
NCI-2019-07963
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Cancer Type
Leukemia
NCT ID
NCT06226571
Protocol IDs
SNDX-5613-0708
NCI-2024-01922
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05490446
Protocol IDs
AG946-C-002
NCI-2023-00894
2022-500609-42-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
NCORP Trial
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05473910
Protocol IDs
TSCAN-001
NCI-2022-06900
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
16.
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCT ID
NCT04293562
Protocol IDs
AAML1831
AAML1831
NCI-2020-00546
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
18.
NCORP Trial
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03914625
Protocol IDs
AALL1731
AALL1731
NCI-2019-02187
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
19.
A Study to Learn More About the Health of Persons with Down Syndrome After Treatment for Acute Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05702645
Protocol IDs
ALTE22C1
ALTE22C1
ALTE22C1
NCI-2022-09410
20.
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04849910
Protocol IDs
VBP101
NCI-2022-00073
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Cancer Type
Leukemia
NCT ID
NCT05487651
Protocol IDs
ATX-K502-001
NCI-2022-07299
ATX K502-001
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Cancer Type
Leukemia
NCT ID
NCT05384587
Protocol IDs
CABL001AUS08
NCI-2023-02252
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03233854
Protocol IDs
CCT5001
NCI-2017-01291
Treatment Sites (1)
24.
Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence
Cancer Type
Leukemia
NCT ID
NCT05587582
Protocol IDs
I 1832021
NCI-2021-09311
25.
Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04798339
Protocol IDs
MCC-20552
NCI-2021-02281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
27.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
NCT ID
NCT01120353
Protocol IDs
CCSS
U24CA055727
Treatment Sites (2)
28.
Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT01787409
Protocol IDs
LS1293
P30CA015083
NCI-2013-00037
Mod12-007862-13
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05143996
Protocol IDs
CLN-049-001
NCI-2021-13598
2020-005195-35
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
33.
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04802161
Protocol IDs
10434
10434
NCI-2021-01961
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
NCORP Trial
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
36.
NCORP Trial
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT06128044
Protocol IDs
CB12A
NCI-2024-01081
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
37.
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04278768
Protocol IDs
CA-4948-102
NCI-2020-03930
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
38.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT05552469
Protocol IDs
CDFV890G12101
NCI-2023-01291
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
40.
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT05776134
Protocol IDs
KT-US-472-0141
Treatment Sites (1)
41.
NCORP Trial
Financial Difficulty in Patients with Blood Cancer
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05212233
Protocol IDs
LCCC2063
NCI-2022-10367
Treatment Sites (1)
42.
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Cancer Type
Leukemia
NCT ID
NCT04928599
Protocol IDs
ACCL20N1CD
ACCL20N1CD
COG-ACCL20N1CD
NCI-2021-03567
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
44.
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma
NCT ID
NCT04824794
Protocol IDs
GCT3014-01
NCI-2021-05589
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
46.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Cancer Type
Cancer-Related Syndrome, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04904588
Protocol IDs
ACCESS
NCI-2021-06605
47.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02530034
Protocol IDs
2014-0057
NCI-2015-02131
P-TRP-2447-14
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
48.
NCORP Trial
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03007147
Protocol IDs
AALL1631
AALL1631
NCI-2016-01588
AALL1631
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
50.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
51.
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03150693
Protocol IDs
A041501
A041501
NCI-2016-01981
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
NCORP Trial
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type
Leukemia, Testicular Cancer
NCT ID
NCT03959085
Protocol IDs
AALL1732
AALL1732
NCI-2019-02845
Treatment Sites (3)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
53.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
54.
55.
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Cancer Type
Leukemia
NCT ID
NCT05429632
Protocol IDs
Priothera SAS
NCI-2022-10700
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
56.
NCORP Trial
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Cancer Type
Leukemia
NCT ID
NCT05224661
Protocol IDs
MEASURE
NCI-2022-03314
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
57.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03779854
Protocol IDs
RG1003345
9880
NCI-2018-01752
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
58.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
59.
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Cancer Type
Leukemia
NCT ID
NCT04872478
Protocol IDs
2843-1003
NCI-2021-13604
60.
NCORP Trial
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
Cancer Type
Leukemia
NCT ID
NCT03960840
Protocol IDs
CYTB323A12101
NCI-2020-08168
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
61.
NCORP Trial
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
62.
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation for the Treatment of Blood Cancer in Patients Undergoing Donor Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT04191187
Protocol IDs
MCC-20131
NCI-2019-08483
Treatment Sites (1)
63.
Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT03610971
Protocol IDs
MCC-19660
NCI-2019-08022
HJKC3-0002
65.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Cancer Type
Leukemia
NCT ID
NCT03793478
Protocol IDs
AC220-A-U202
NCI-2019-02948
2016-002919-18
66.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT06001788
Protocol IDs
KO-MEN-008
NCI-2023-06933
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
67.
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
68.
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT05878184
Protocol IDs
SC291-101
NCI-2023-04424
Treatment Sites (1)
69.
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
Treatment Sites (1)
70.
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Cancer Type
Leukemia, Multiple Myeloma
NCT ID
NCT05153330
Protocol IDs
COVALENT-101
NCI-2021-14401
BF-MNN-101
Treatment Sites (1)
71.
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT04789655
Protocol IDs
CC-96191-AML-001
NCI-2021-02783
U1111-1264-5412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
72.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type
Leukemia
NCT ID
NCT04260022
Protocol IDs
HQP1351CU101
NCI-2020-01100
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCT ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
74.
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Cancer Type
Leukemia
NCT ID
NCT06073821
Protocol IDs
BGB-11417-301
NCI-2023-09813
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
75.
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04245397
Protocol IDs
SX682-MDS-102
NCI-2020-04523
R44HL142389-01
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
76.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
77.
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT05602194
Protocol IDs
ACCL1931
ACCL1931
COG-ACCL1931
NCI-2022-08058
78.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
79.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
80.
TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
Cancer Type
Leukemia
NCT ID
NCT06088888
Protocol IDs
TGRX-678-07-101
NCI-2023-10579
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
82.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
83.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
84.
NCORP Trial
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02775383
Protocol IDs
NHLBI-MDS
NCI-2016-00281
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
85.
Treosulfan-Based Conditioning Regimen before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04965597
Protocol IDs
RG1121820
NCI-2021-13862
BMT CTN 1904
86.
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05183035
Protocol IDs
ITCC-101/APAL2020D
NCI-2022-07200
2021-003212-11
88.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03842696
Protocol IDs
UMCC 2018.081
NCI-2019-04695
HUM00147796
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180